SG11202012029PA - Methods and compositions for inhibition of dihydroorotate dehydrogenase - Google Patents
Methods and compositions for inhibition of dihydroorotate dehydrogenaseInfo
- Publication number
- SG11202012029PA SG11202012029PA SG11202012029PA SG11202012029PA SG11202012029PA SG 11202012029P A SG11202012029P A SG 11202012029PA SG 11202012029P A SG11202012029P A SG 11202012029PA SG 11202012029P A SG11202012029P A SG 11202012029PA SG 11202012029P A SG11202012029P A SG 11202012029PA
- Authority
- SG
- Singapore
- Prior art keywords
- inhibition
- compositions
- methods
- dihydroorotate dehydrogenase
- dihydroorotate
- Prior art date
Links
- 108010052167 Dihydroorotate Dehydrogenase Proteins 0.000 title 1
- 102100032823 Dihydroorotate dehydrogenase (quinone), mitochondrial Human genes 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
- C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862688612P | 2018-06-22 | 2018-06-22 | |
| PCT/US2019/038622 WO2019246603A1 (en) | 2018-06-22 | 2019-06-22 | Methods and compositions for inhibition of dihydroorotate dehydrogenase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202012029PA true SG11202012029PA (en) | 2021-01-28 |
Family
ID=68984309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202012029PA SG11202012029PA (en) | 2018-06-22 | 2019-06-22 | Methods and compositions for inhibition of dihydroorotate dehydrogenase |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US11312686B2 (https=) |
| EP (2) | EP4438042A3 (https=) |
| JP (1) | JP7373170B2 (https=) |
| KR (1) | KR102821649B1 (https=) |
| CN (1) | CN112672744B (https=) |
| AU (2) | AU2019288813B2 (https=) |
| BR (1) | BR112020026308A2 (https=) |
| CA (1) | CA3103557A1 (https=) |
| ES (1) | ES2994093T3 (https=) |
| IL (1) | IL279586B (https=) |
| MX (1) | MX2021000143A (https=) |
| SG (1) | SG11202012029PA (https=) |
| WO (1) | WO2019246603A1 (https=) |
| ZA (1) | ZA202007620B (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3773579A4 (en) | 2018-03-26 | 2022-03-09 | Clear Creek Bio, Inc. | COMPOSITIONS AND METHODS FOR INHIBITING DIHYDROOROTATE DEHYDROGENASE |
| WO2021134045A1 (en) * | 2019-12-26 | 2021-07-01 | Ohio State Innovation Foundation | Methods and compositions for inhibition of dihydroorotate dehydrogenase in combination with an anti-cd38 therapeutic agent |
| AU2020411507A1 (en) * | 2019-12-26 | 2022-07-14 | Hendrix College | Methods and compositions for inhibition of dihydroorotate dehydrogenase |
| EP4121050A4 (en) * | 2020-03-20 | 2024-04-17 | Clear Creek Bio, Inc. | STABLE POLYMORPHOUS COMPOSITIONS OF BREQUINA SODIUM, METHODS OF USE AND PRODUCTION THEREOF |
| US20210300873A1 (en) | 2020-03-20 | 2021-09-30 | Clear Creek Bio, Inc. | Stable polymorphic compositions of brequinar sodium and methods of use and manufacture thereof |
| CN113943312A (zh) * | 2020-07-17 | 2022-01-18 | 轶诺(浙江)药业有限公司 | 一类肠道裂解型共药及其制备和用途 |
| WO2023278778A1 (en) * | 2021-06-30 | 2023-01-05 | Ohio State Innovation Foundation | Methods and compositions for inhibition of dihydroorotate dehydrogenase in combination with an anti-cd47-sirpα therapeutic agent |
| CN115896025B (zh) * | 2021-08-20 | 2025-08-26 | 合肥中科普瑞昇生物医药科技有限公司 | 人原代急性髓系白血病细胞的培养基及培养方法 |
| US20250009740A1 (en) * | 2021-11-22 | 2025-01-09 | Ohio State Innovation Foundation | Methods and compositions for targeting alternative metabolism along with flt3 inhibitor-mediated antileukemic actions |
| CN115532290B (zh) * | 2022-10-13 | 2024-04-30 | 浙江昌海制药有限公司 | 一种特定晶面选择性氢化催化剂及其制备方法和应用 |
| WO2025227007A1 (en) * | 2024-04-26 | 2025-10-30 | Ohio State Innovation Foundation | Methods and compositions for inhibition of dihydroorotate dehydrogenase |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2888346A (en) * | 1955-08-22 | 1959-05-26 | Gen Aniline & Film Corp | Ultra-violet absorbing compounds |
| AU2896097A (en) * | 1996-05-10 | 1997-12-05 | Novartis Ag | Use of brequinar and derivatives in chronic rejection of allografts and xenotransplantation |
| JP2003510352A (ja) * | 1999-10-01 | 2003-03-18 | インスティチュート オブ モレキュラー アンド セル バイオロジー | ウイルス媒介性疾病の治療用化合物 |
| US6841561B1 (en) | 1999-10-01 | 2005-01-11 | Institute Of Molecular And Cell Biology | Dihydroorotate dehydrogenase inhibitors for the treatment of viral-mediated diseases |
| HRPK20041072B3 (hr) * | 2002-05-17 | 2007-07-31 | Aventis Pharma S.A. | Primjena docetaxela/doxorubicina/ciklofosfamida uadjuvantnoj terapiji karcinoma dojke i jajnika |
| EP2948450A4 (en) | 2013-01-28 | 2016-11-09 | Viamet Pharmaceuticals Inc | METALLOENZYMINHIBITORVERBINDUNGEN |
| HRP20181908T1 (hr) | 2013-02-25 | 2019-01-11 | Aurigene Discovery Technologies Limited | Derivati trosupstituiranog benzotriazola kao inhibitori dihidroorotat oksigenaze |
| US20190192501A1 (en) * | 2016-08-23 | 2019-06-27 | Icahn School Of Medicine At Mount Sinai | Methods for treating pten-mutant tumors |
-
2019
- 2019-06-22 WO PCT/US2019/038622 patent/WO2019246603A1/en not_active Ceased
- 2019-06-22 CN CN201980042068.7A patent/CN112672744B/zh active Active
- 2019-06-22 CA CA3103557A patent/CA3103557A1/en active Pending
- 2019-06-22 US US17/253,342 patent/US11312686B2/en active Active
- 2019-06-22 BR BR112020026308-7A patent/BR112020026308A2/pt not_active Application Discontinuation
- 2019-06-22 AU AU2019288813A patent/AU2019288813B2/en active Active
- 2019-06-22 EP EP24181542.2A patent/EP4438042A3/en active Pending
- 2019-06-22 ES ES19822319T patent/ES2994093T3/es active Active
- 2019-06-22 JP JP2021520287A patent/JP7373170B2/ja active Active
- 2019-06-22 SG SG11202012029PA patent/SG11202012029PA/en unknown
- 2019-06-22 KR KR1020217002054A patent/KR102821649B1/ko active Active
- 2019-06-22 MX MX2021000143A patent/MX2021000143A/es unknown
- 2019-06-22 EP EP19822319.0A patent/EP3793562B1/en active Active
-
2020
- 2020-12-07 ZA ZA2020/07620A patent/ZA202007620B/en unknown
- 2020-12-20 IL IL279586A patent/IL279586B/en unknown
-
2021
- 2021-11-10 US US17/523,675 patent/US11999697B2/en active Active
-
2023
- 2023-09-19 AU AU2023233065A patent/AU2023233065B2/en active Active
-
2024
- 2024-04-26 US US18/647,273 patent/US20240294477A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN112672744A (zh) | 2021-04-16 |
| AU2023233065B2 (en) | 2025-09-25 |
| US11999697B2 (en) | 2024-06-04 |
| AU2019288813B2 (en) | 2023-06-29 |
| IL279586A (en) | 2021-01-31 |
| AU2023233065A1 (en) | 2023-10-05 |
| KR20210048483A (ko) | 2021-05-03 |
| JP7373170B2 (ja) | 2023-11-02 |
| US20240294477A1 (en) | 2024-09-05 |
| IL279586B (en) | 2021-09-30 |
| US20210253531A1 (en) | 2021-08-19 |
| ES2994093T3 (en) | 2025-01-17 |
| MX2021000143A (es) | 2021-08-05 |
| EP4438042A2 (en) | 2024-10-02 |
| EP4438042A3 (en) | 2024-12-04 |
| BR112020026308A2 (pt) | 2021-03-30 |
| US11312686B2 (en) | 2022-04-26 |
| WO2019246603A1 (en) | 2019-12-26 |
| EP3793562A4 (en) | 2021-07-07 |
| US20220064119A1 (en) | 2022-03-03 |
| CA3103557A1 (en) | 2019-12-26 |
| EP3793562A1 (en) | 2021-03-24 |
| JP2021530559A (ja) | 2021-11-11 |
| CN112672744B (zh) | 2022-10-14 |
| AU2019288813A1 (en) | 2021-01-07 |
| ZA202007620B (en) | 2023-02-22 |
| EP3793562B1 (en) | 2024-06-19 |
| KR102821649B1 (ko) | 2025-06-17 |
| EP3793562C0 (en) | 2024-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL279586B (en) | Methods and compositions for the inhibition of dihydroorotate dehydrogenase | |
| IL273875A (en) | Methods and compounds for inhibiting expression of LDHA | |
| SG11202105769XA (en) | Inhibitors of apol1 and methods of using same | |
| IL281939A (en) | VAP-1 inhibitors | |
| IL287268A (en) | Dihydrourotate dehydrogenase inhibitors | |
| SG11202107639UA (en) | Compositions and methods for inhibition of lineage specific antigens | |
| IL287973A (en) | acss2 inhibitors and methods of their use | |
| IL284537A (en) | Dihydrourotate dehydrogenase inhibitors | |
| IL276135A (en) | Preparations and methods of use | |
| IL284989A (en) | Dihydrourotate dehydrogenase inhibitors | |
| IL281815A (en) | VAP-1 inhibitors | |
| ZA202100780B (en) | Bismuth-thiol compositions and methods of use | |
| GB202105087D0 (en) | Microbial compositions and methods of use | |
| IL289127A (en) | ppm1a inhibitors and methods of using them | |
| IL282533A (en) | Oligosaccharide preparations and methods of using them | |
| EP3687514A4 (en) | METHODS AND COMPOSITIONS FOR INHIBITING STAT3 | |
| IL287797A (en) | Oligosaccharide preparations and methods of use | |
| EP3555079A4 (en) | INHIBITORS OF MUTANT ISOCITRATEHYDROGENASES AND COMPOSITIONS AND METHODS FOR THEREOF | |
| EP3773579A4 (en) | COMPOSITIONS AND METHODS FOR INHIBITING DIHYDROOROTATE DEHYDROGENASE | |
| EP3526221A4 (en) | INHIBITORS OF MUTANTS ISOCITRATE DEHYDROGENASES AND COMPOSITIONS AND METHODS THEREFOR | |
| EP3658563A4 (en) | INHIBITORS OF MUTANT ISOCITRATEHYDROGENASES AND COMPOSITIONS AND METHODS FOR THEREOF | |
| EP3616705A4 (en) | COMPOSITION WITH AMOMUM VILLOSUM TO IMPROVE THE PREVENTION AND TREATMENT OF FATTY LIVER | |
| GB201810923D0 (en) | Compositions and method of treatment | |
| IL285367A (en) | Methods and compounds for inhibiting the expression of cyp27a1 | |
| GB201919385D0 (en) | Compositions and methods of manufacture |